Loading...

Soligenix

Nasdaq:SNGX
Snowflake Description

High growth potential with mediocre balance sheet.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
SNGX
Nasdaq
$13M
Market Cap
  1. Home
  2. US
  3. Pharmaceuticals & Biotech
Company description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The last earnings update was 6 days ago. More info.


Add to Portfolio Compare Print
  • Soligenix has significant price volatility in the past 3 months.
SNGX Share Price and Events
7 Day Returns
2.5%
NasdaqCM:SNGX
-1.6%
US Biotechs
-0.7%
US Market
1 Year Returns
-53.9%
NasdaqCM:SNGX
-5.5%
US Biotechs
3%
US Market
SNGX Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Soligenix (SNGX) 2.5% -6.6% -18.9% -53.9% -89.4% -96%
US Biotechs -1.6% -5.5% -6.5% -5.5% 9.7% 12%
US Market -0.7% -2% 2.4% 3% 39.2% 42%
1 Year Return vs Industry and Market
  • SNGX underperformed the Biotechs industry which returned -5.5% over the past year.
  • SNGX underperformed the Market in United States of America which returned 3% over the past year.
Price Volatility
SNGX
Industry
5yr Volatility vs Market

SNGX Value

 Is Soligenix undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Soligenix. This is due to cash flow or dividend data being unavailable. The share price is $0.7381.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Soligenix's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Soligenix's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
NasdaqCM:SNGX PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $-0.53
NasdaqCM:SNGX Share Price ** NasdaqCM (2019-05-17) in USD $0.74
United States of America Biotechs Industry PE Ratio Median Figure of 34 Publicly-Listed Biotechs Companies 19.48x
United States of America Market PE Ratio Median Figure of 3,088 Publicly-Listed Companies 17.89x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Soligenix.

NasdaqCM:SNGX PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:SNGX Share Price ÷ EPS (both in USD)

= 0.74 ÷ -0.53

-1.4x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Soligenix is loss making, we can't compare its value to the US Biotechs industry average.
  • Soligenix is loss making, we can't compare the value of its earnings to the United States of America market.
Price based on expected Growth
Does Soligenix's expected growth come at a high price?
Raw Data
NasdaqCM:SNGX PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -1.4x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
62.9%per year
United States of America Biotechs Industry PEG Ratio Median Figure of 27 Publicly-Listed Biotechs Companies 1.32x
United States of America Market PEG Ratio Median Figure of 2,117 Publicly-Listed Companies 1.56x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Soligenix, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Soligenix's assets?
Raw Data
NasdaqCM:SNGX PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $0.29
NasdaqCM:SNGX Share Price * NasdaqCM (2019-05-17) in USD $0.74
United States of America Biotechs Industry PB Ratio Median Figure of 416 Publicly-Listed Biotechs Companies 3.21x
United States of America Market PB Ratio Median Figure of 5,195 Publicly-Listed Companies 1.83x
NasdaqCM:SNGX PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:SNGX Share Price ÷ Book Value per Share (both in USD)

= 0.74 ÷ 0.29

2.54x

* Primary Listing of Soligenix.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Soligenix is good value based on assets compared to the US Biotechs industry average.
X
Value checks
We assess Soligenix's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Soligenix has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

SNGX Future Performance

 How is Soligenix expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
62.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Soligenix expected to grow at an attractive rate?
  • Soligenix's earnings growth is expected to exceed the low risk savings rate of 2.7%.
Growth vs Market Checks
  • Soligenix's earnings growth is expected to exceed the United States of America market average.
  • Soligenix's revenue growth is expected to exceed the United States of America market average.
Annual Growth Rates Comparison
Raw Data
NasdaqCM:SNGX Future Growth Rates Data Sources
Data Point Source Value (per year)
NasdaqCM:SNGX Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 62.9%
NasdaqCM:SNGX Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 56.3%
United States of America Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.6%
United States of America Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 17.5%
United States of America Market Earnings Growth Rate Market Cap Weighted Average 13.9%
United States of America Market Revenue Growth Rate Market Cap Weighted Average 7.3%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
NasdaqCM:SNGX Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
NasdaqCM:SNGX Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 90 67 1
2022-12-31 53 30 2
2021-12-31 24 -9 2
2020-12-31 6 -12 2
2019-12-31 6 -10 2
NasdaqCM:SNGX Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 5 -8 -8
2018-12-31 5 -7 -9
2018-09-30 6 -7 -8
2018-06-30 6 -7 -7
2018-03-31 5 -6 -8
2017-12-31 5 -7 -7
2017-09-30 6 -6 -5
2017-06-30 7 -6 -6
2017-03-31 9 -6 -4
2016-12-31 10 -5 -3
2016-09-30 12 -5 -5
2016-06-30 13 -4 -1

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Soligenix's earnings are expected to grow significantly at over 20% yearly.
  • Soligenix's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
NasdaqCM:SNGX Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (1 month ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Soligenix Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SNGX Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 2.56 2.56 2.56 1.00
2022-12-31 1.25 1.25 1.24 2.00
2021-12-31 -0.34 -0.20 -0.48 2.00
2020-12-31 -0.55 -0.48 -0.65 3.00
2019-12-31 -0.52 -0.52 -0.52 1.00
NasdaqCM:SNGX Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 -0.53
2018-12-31 -0.68
2018-09-30 -0.74
2018-06-30 -0.91
2018-03-31 -1.12
2017-12-31 -1.16
2017-09-30 -1.02
2017-06-30 -1.29
2017-03-31 -0.94
2016-12-31 -0.93
2016-09-30 -1.59
2016-06-30 -0.18

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Soligenix will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Soligenix's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United States of America market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United States of America market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Soligenix has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

SNGX Past Performance

  How has Soligenix performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Soligenix's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Soligenix does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Soligenix's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Soligenix's 1-year growth to the US Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
Soligenix's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Soligenix Company Filings, last reported 1 month ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

NasdaqCM:SNGX Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 5.27 -8.16 3.09 6.59
2018-12-31 5.24 -8.90 2.95 6.75
2018-09-30 5.52 -7.93 2.93 6.28
2018-06-30 5.96 -7.04 2.98 5.48
2018-03-31 5.22 -7.79 3.18 6.09
2017-12-31 5.43 -7.15 3.21 5.51
2017-09-30 5.84 -5.34 3.23 4.47
2017-06-30 6.98 -6.05 3.16 5.04
2017-03-31 9.15 -3.83 3.32 4.08
2016-12-31 10.45 -3.25 3.43 4.30
2016-09-30 11.72 -4.97 3.59 5.10
2016-06-30 12.64 -0.53 3.78 5.18
2016-03-31 10.58 -4.41 3.66 5.80
2015-12-31 8.77 -7.83 3.60 5.40
2015-09-30 7.72 -3.85 3.50 5.49
2015-06-30 6.63 -10.97 3.39 5.32
2015-03-31 6.95 -7.94 3.38 5.09
2014-12-31 7.04 -6.71 3.40 5.09
2014-09-30 6.50 -7.64 3.28 4.29
2014-06-30 4.02 -9.85 3.26 4.42
2014-03-31 3.23 -12.30 3.12 5.35
2013-12-31 3.22 -10.06 2.77 5.07
2013-09-30 2.65 -12.04 2.64 4.97
2013-06-30 3.27 -6.24 2.49 4.13
2013-03-31 3.40 -3.81 2.40 2.49
2012-12-31 3.14 -4.16 2.56 2.61
2012-09-30 3.00 -4.11 2.41 2.70
2012-06-30 7.86 -1.15 2.45 4.68

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Soligenix has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Soligenix has efficiently used its assets last year compared to the US Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Soligenix improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Soligenix's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Soligenix has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

SNGX Health

 How is Soligenix's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Soligenix's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Soligenix is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Soligenix's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Soligenix's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 40.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Soligenix Company Filings, last reported 1 month ago.

NasdaqCM:SNGX Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 5.28 0.23 7.20
2018-12-31 6.28 0.00 8.98
2018-09-30 9.27 0.00 11.72
2018-06-30 2.62 0.00 4.24
2018-03-31 4.07 0.00 6.37
2017-12-31 6.32 0.00 7.81
2017-09-30 3.14 0.00 5.00
2017-06-30 3.62 0.00 5.81
2017-03-31 5.82 0.00 7.14
2016-12-31 7.40 0.00 8.77
2016-09-30 2.17 0.00 5.66
2016-06-30 0.03 0.00 3.18
2016-03-31 -1.05 0.30 4.26
2015-12-31 -0.02 0.29 4.92
2015-09-30 -0.47 0.29 4.03
2015-06-30 -3.52 0.00 4.04
2015-03-31 -1.83 0.00 5.01
2014-12-31 -0.15 0.00 5.53
2014-09-30 -4.28 0.00 4.21
2014-06-30 -4.66 0.00 5.04
2014-03-31 -4.11 0.00 5.61
2013-12-31 -1.77 0.00 5.86
2013-09-30 -3.60 0.00 6.58
2013-06-30 2.45 0.00 8.13
2013-03-31 2.58 0.00 2.61
2012-12-31 3.55 0.00 3.36
2012-09-30 4.02 0.00 3.70
2012-06-30 4.62 0.00 4.43
  • Soligenix's level of debt (4.3%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has increased over the past 5 years (0% vs 4.3% today).
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Soligenix has less than a year of cash runway based on current free cash flow.
  • Soligenix has less than a year of cash runway if free cash flow continues to grow at historical rates of 19.6% each year.
X
Financial health checks
We assess Soligenix's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Soligenix has a total score of 3/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

SNGX Dividends

 What is Soligenix's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Soligenix dividends.
If you bought $2,000 of Soligenix shares you are expected to receive $0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Soligenix's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Soligenix's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
NasdaqCM:SNGX Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Global Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 19 Stocks 2.4%
United States of America Market Average Dividend Yield Market Cap Weighted Average of 2000 Stocks 2.5%
United States of America Minimum Threshold Dividend Yield 10th Percentile 0.8%
United States of America Bottom 25% Dividend Yield 25th Percentile 1.4%
United States of America Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

NasdaqCM:SNGX Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31
2019-12-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Soligenix has not reported any payouts.
  • Unable to verify if Soligenix's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Soligenix's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Soligenix has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Soligenix's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Soligenix afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Soligenix has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

SNGX Management

 What is the CEO of Soligenix's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Christopher Schaber
COMPENSATION $618,592
AGE 52
TENURE AS CEO 12.8 years
CEO Bio

Dr. Christopher J. Schaber, Ph.D., has been the President and Chief Executive Officer at Soligenix, Inc. (Formerly DOR BioPharma Inc.) since August 30, 2006. Dr. Schaber has more than 23 years experience in the pharmaceutical and biotechnology industry. Prior to joining the company, Dr. Schaber served from 1998 to 2006 as an Executive Vice President and Chief Operating Officer of Discovery Laboratories, Inc., where he was responsible for overall pipeline development and key areas of commercial operations, including regulatory affairs, quality control and assurance, manufacturing and distribution, preclinical and clinical research and medical affairs, as well as coordination of commercial launch preparation activities. During his tenure at Discovery Laboratories, Inc., Dr. Schaber played a significant role in raising over $150 million through both public offerings and private placements. Previously, he held positions of Executive Vice President of Drug Development and Regulatory Compliance since April 1999 and Chief Development Officer and Vice President of Regulatory Affairs and Quality Assurance Quality Control since June 1998. From 1996 to 1998, he was a co-founder of Acute Therapeutics, Inc., and served as its Vice President of Regulatory Compliance, Quality Assurance and Drug Development. He served as a Director of Worldwide Regulatory Affairs and Operations for Ohmeda PPD, Inc. from 1994 to 1996. He held a variety of regulatory positions of increasing importance with Liposome Company, Inc. and Elkins-Sinn Inc., a division of Wyeth-Ayerst Laboratories from 1989 to 1994. Dr. Schaber also served as an NDA and FDA regulatory strategic advisor to DOR. He has been the Chairman of Soligenix, Inc. since October 8, 2009. He has been the Chairman of BioNJ Inc. since February 2019 and served as its Vice Chairman. He has been Director at Soligenix, Inc. since August 30, 2006. He also serves as a Director of Alliance for BioSecurity and BioNJ Inc. He is a member of the corporate councils for both the National Organization for Rare Diseases (NORD) and the American Society for Blood and Marrow Transplantation (ASBMT). Dr. Schaber holds a Regulatory Affairs Certification (RAC) from Regulatory Affairs Professional Society. Dr. Schaber holds a B.A. from Western Maryland College and an M.S. in Pharmaceutics from Temple University and Ph.D. in Pharmaceutical Sciences from The Union Graduate School.

CEO Compensation
  • Christopher's compensation has been consistent with company performance over the past year.
  • Christopher's remuneration is higher than average for companies of similar size in United States of America.
Management Team Tenure

Average tenure and age of the Soligenix management team in years:

4.9
Average Tenure
64
Average Age
  • The tenure for the Soligenix management team is about average.
Management Team

Christopher Schaber

TITLE
Chairman
COMPENSATION
$619K
AGE
52
TENURE
12.8 yrs

Karen Krumeich

TITLE
CFO, Senior VP & Corporate Secretary
COMPENSATION
$309K
AGE
64
TENURE
2.9 yrs

Oreola Donini

TITLE
Senior VP & Chief Scientific Officer
COMPENSATION
$302K
AGE
46
TENURE
4.4 yrs

Richard Straube

TITLE
Senior VP & Chief Medical Officer
COMPENSATION
$432K
AGE
66
TENURE
5.3 yrs

Richard Dunning

TITLE
Executive Officer
AGE
72
Board of Directors Tenure

Average tenure and age of the Soligenix board of directors in years:

9.6
Average Tenure
66
Average Age
  • The tenure for the Soligenix board of directors is about average.
Board of Directors

Christopher Schaber

TITLE
Chairman
COMPENSATION
$619K
AGE
52
TENURE
9.6 yrs

Robert Rubin

TITLE
Independent Director
COMPENSATION
$83K
AGE
72
TENURE
9.6 yrs

Keith Brownlie

TITLE
Independent Director
COMPENSATION
$85K
AGE
66
TENURE
7.9 yrs

Jerry Zeldis

TITLE
Independent Director
COMPENSATION
$80K
AGE
68
TENURE
7.9 yrs

George McDonald

TITLE
Member of Acute Radiation Syndrome Sci & Radiation Enteritis Med

William Small

TITLE
Member of Radiation Enteritis Medical Advisory Board

Marvin Rotman

TITLE
Member of Radiation Enteritis Medical Advisory Board

Lisa Kachnic

TITLE
Member of Radiation Enteritis Medical Advisory Board

Gregg Lapointe

TITLE
Independent Director
COMPENSATION
$78K
AGE
59
TENURE
10.2 yrs

Jeffrey Hyams

TITLE
Member of Pediatric Crohn's Disease Medical Advisory Board
Who owns this company?
Recent Insider Trading
  • More shares have been bought than sold by Soligenix insiders in the past 3 months, but not in substantial volumes.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price ($) Value ($)
22. Apr 19 Buy Jerome Zeldis Individual 22. Apr 19 22. Apr 19 10,000 $0.73 $7,274
22. Apr 19 Buy Christopher Schaber Individual 22. Apr 19 22. Apr 19 5,000 $0.72 $3,577
18. Oct 18 Buy Christopher Schaber Individual 18. Oct 18 18. Oct 18 8,700 $1.17 $10,177
18. Oct 18 Buy Mark Pearson Individual 17. Oct 18 17. Oct 18 170,000 $1.16 $197,200
22. Aug 18 Buy Christopher Schaber Individual 22. Aug 18 22. Aug 18 3,530 $1.42 $5,012
X
Management checks
We assess Soligenix's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Soligenix has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

SNGX News

Simply Wall St News

What You Must Know About Soligenix Inc's (NASDAQ:SNGX) Major Investors

In this article, I'm going to take a look at Soligenix Inc’s (NASDAQ:SNGX) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … When it comes to ownership structure of a company, the impact has been observed in both the long-and short-term performance of shares. … Therefore, it is beneficial for us to examine SNGX's ownership structure in more detail.

Simply Wall St -

Soligenix Inc's (NASDAQ:SNGX) Path To Profitability

The company’s loss has recently broadened since it announced a -US$7.15m loss in the full financial year, compared to the latest trailing-twelve-month loss of -US$7.79m, moving it further away from breakeven?

Simply Wall St -

Who Are The Major Shareholders In Soligenix Inc (NASDAQ:SNGX)?

This level of ownership gives retail investors the power to sway key policy decisions such as board composition, executive compensation, and potential acquisitions. … Private Company Ownership Potential investors in SNGX should also look at another important group of investors: private companies, with a stake of 3.35%, who are primarily invested because of strategic and capital gain interests. … Thus, investors not need worry too much about the consequences of these holdings.Next Steps: Although SNGX has a low level of overall institutional ownership, active hedge funds still have a significant stake in the company.

Simply Wall St -

Soligenix Inc's (NASDAQ:SNGX) Shift From Loss To Profit

In this article, I will touch on the expectations for SNGX’s growth and when analysts expect the company to become profitable. … Working backwards from analyst estimates, it turns out that they expect the company to grow 48.98% year-on-year, on average, which is rather optimistic! … Next Steps: There are too many aspects of SNGX to cover in one brief article, but the key fundamentals for the company can all be found in one place – SNGX’s company page on Simply Wall St.

Simply Wall St -

Soligenix Inc (NASDAQ:SNGX): Will The Growth Last?

Soligenix Inc's (NASDAQ:SNGX) most recent earnings announcement in December 2017 indicated that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below, I've laid out key numbers on how market analysts view Soligenix's earnings growth outlook over the next couple of years and whether the future looks brighter. … See our latest analysis for Soligenix Analysts' outlook for next year seems pessimistic, with earnings becoming even more negative, generating -US$11.29M in 2019. … The slope of this line is the rate of earnings growth, which in this case is 48.98%.

Simply Wall St -

Soligenix Inc (NASDAQ:SNGX): Does The Earnings Decline Make It An Underperformer?

For investors with a long-term horizon, examining earnings trend over time and against industry peers is more insightful than looking at an earnings announcement in one point in time. … Check out our latest analysis for Soligenix Was SNGX's recent earnings decline worse than the long-term trend and the industry? … I look at data from the most recent 12 months, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data.

Simply Wall St -

With 36.2% EPS Drop, Should Soligenix Inc's (SNGX) Recent Track Record Be A Cause Of Concern?

Below, I will run you through a simple sense check to build perspective on how Soligenix is doing by comparing its most recent earnings with its historical trend, in addition to the performance of its biotechnology industry peers. … To account for any quarterly or half-yearly updates, I use the ‘latest twelve-month’ data, which annualizes the most recent half-year data, or in some cases, the latest annual report is already the most recent financial year data. … For Soligenix, the latest earnings -$5M, which, relative to the previous year's figure, has become more negative.

Simply Wall St -

Should Your Next Investment In The Healthcare Industry Be In Soligenix Inc (SNGX)?

Moreover, the trend of below-industry growth rate is expected to continue in the future with SNGX poised to deliver a -20.92% growth compared to the industry average growth rate of 6.42%. … SNGX is a biotech industry laggard in terms of its future growth outlook. … If your initial investment thesis is around the growth prospects of SNGX, there are other biotech companies that are expected to deliver higher growth in the future, and perhaps trading at a discount to the industry average.

Simply Wall St -

SNGX Company Info

Description

Soligenix, Inc., a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. It operates in two segments, BioTherapeutics and Vaccines/BioDefense. The BioTherapeutics segment develops SGX301, a photodynamic therapy, which is in Phase 3 clinical trial to treat cutaneous T-cell lymphoma; and SGX942, an innate defense regulator technology which is in Phase 3 clinical trial to treat oral mucositis in head and neck cancer. This segment also offers proprietary formulations of oral beclomethasone 17,21-dipropionate, which is in Phase 1/2 clinical trial for the prevention/treatment of gastrointestinal (GI) disorders characterized by severe inflammation, including pediatric Crohn’s disease and acute radiation enteritis. The Vaccines/BioDefense segment is involved in the development of RiVax, a ricin toxin vaccine candidate, which has completed Phase 1a and 1b clinical trials for the treatment of vaccine against ricin toxin poisoning; OrbeShield, a GI acute radiation syndrome (GI ARS) therapeutic candidate, which is in pre-clinical stage to treat therapeutics against GI ARS; and SGX943, a melioidosis therapeutic candidate that is in pre-clinical stage for the treatment of emerging and/or antibiotic-resistant infectious diseases, as well as ThermoVax, which is indicated for the thermostability of aluminum adjuvanted vaccine for ricin. The company was formerly known as DOR BioPharma, Inc. and changed its name to Soligenix, Inc. in 2009. Soligenix, Inc. was incorporated in 1987 and is headquartered in Princeton, New Jersey.

Details
Name: Soligenix, Inc.
SNGX
Exchange: NasdaqCM
Founded: 1987
$13,425,454
18,189,208
Website: http://www.soligenix.com
Address: Soligenix, Inc.
29 Emmons Drive,
Suite B-10,
Princeton,
New Jersey, 08540,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM SNGX Common Stock Nasdaq Capital Market US USD 15. Jun 1987
Number of employees
Current staff
Staff numbers
14
Soligenix employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/20 01:30
End of day share price update: 2019/05/17 00:00
Last estimates confirmation: 2019/05/15
Last earnings filing: 2019/05/14
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.